A Clinical Trial of Adjunctive PRAX-114 in Participants With Major Depressive Disorder
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
This is a randomized, double-blind, placebo-controlled clinical trial to evaluate the
efficacy and safety of 10, 20, 40 and 60 mg oral PRAX-114 as adjunctive therapy compared to
placebo in the treatment of adults with MDD who had an inadequate response to their current
antidepressant treatment. A sub-study to investigate the pharmacokinetics (PK) of PRAX-114
and metabolites when dosed in the evening in participants with MDD will be conducted in a
subset of participants at selected research sites with serial PK sampling capabilities.